The lead program, icosabutate, is the first-in-class Structurally Engineered Fatty Acid (SEFA) in late stage clinical development for NASH.

Non-Alcoholic SteatoHepatitis (NASH) is the leading cause of liver disease affecting an estimated 15-30 million patients in the US, western Europe and Japan. Today the treatment options available to NASH patients are limited. In addition to targeting NASH, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.